Full-Time

Genetic Implementation Manager

Deadline 8/1/27
Genus

Genus

1,001-5,000 employees

Global animal genetics and breeding technology

No salary listed

Spain

In Person

Ideally based in Spain, with approximately 30–40% travel including some international travel.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
Supply Chain Management
Data Analysis

Get referred to Genus

See people who can refer or advise you

Requirements
  • A university degree in Animal or Meat Science, Animal Breeding and Genetics, or a related field.
  • At least 5 years of experience within livestock production systems, including experience in genetic production and training.
  • Working knowledge of contemporary record-keeping systems.
  • At least 4 years of experience with Microsoft Office and other relevant software applications.
  • Must not cohabit or live on the same premises with any person who works with swine or with people who are in routine contact with swine.
Responsibilities
  • Lead the implementation and execution of PIC’s genetic improvement strategy across the Elite Farm system, ensuring consistency, compliance, and achievement of program objectives.
  • Manage and develop direct reports by providing coaching, training, performance feedback, and development opportunities to build a high-performing team.
  • Provide leadership and direction to technical site leads and farm teams to ensure effective adoption and execution of genetic improvement protocols across multiple domestic and international sites.
  • Partner closely with Supply Chain to align implementation of the genetic program with animal flow, farm capacity, and operational planning across the elite farm network.
  • Drive cross-functional coordination and communication of the genetic improvement strategy to promote understanding, alignment, and execution of key priorities and goals.
  • Oversee the execution of routine and special genetic improvement projects, ensuring timelines, resources, and deliverables are effectively managed.
  • Support the planning and coordination of genetic dissemination of elite animals across the global elite farm system in collaboration with internal stakeholders.
  • Provide oversight and support for data acquisition systems, including troubleshooting software and hardware issues and identifying innovative solutions that improve data capture and usability on farms.
  • Analyze and interpret genetic and operational data using statistical techniques and standard methodologies to support decision-making and continuous improvement.
  • Monitor program performance, identify risks or gaps in execution, and implement corrective actions to improve outcomes.
  • Use established procedures and sound judgment to solve operational and technical problems while driving process discipline and continuous improvement.
Desired Qualifications
  • An advanced degree in Animal or Meat Science, Animal Breeding and Genetics, or a related field.

Genus is a global animal-genetics company focused on improving cattle and pig performance through breeding and genetic technologies. It operates two main units, ABS Global for bovine genetics and PIC for porcine genetics, offering breeding animals, reproduction services, and gene-editing and next-generation breeding tools. Its products work by combining genetics, reproductive biology, and data-driven selection to produce healthier herds, higher-quality food, and more efficient production. Genus differentiates itself through its global scale (operations in 30 countries and distribution to over 50 markets), its specialized units for cattle and pigs, and its integration of science with practical farming solutions. Its goal is to sustainably nourish the world by improving animal health, food quality, and the resilience of the global food system, while delivering value to customers and upholding ethical, collaborative values.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Basingstoke, United Kingdom

Founded

1933

Get referred to Genus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FY26 interim results on 26 February 2026 showed record first-half adjusted operating profit.
  • ABS grew genotyping above 30% on 7 May 2026, signaling commercial momentum.
  • 50 million Sexcel units sold by 25 June 2026 proves global scaling.

What critics are saying

  • PIC China deconsolidation removes reported revenue, and 49% ownership cuts control.
  • Genus still depends on regulators in Mexico, Japan, and China for commercialization.
  • If export markets block gene-edited pork, PRRS commercialization stays stranded indefinitely.

What makes Genus unique

  • Genus owns PIC and ABS, spanning pig and bovine genetics globally.
  • Canada approved PRRS-resistant pigs on 23 January 2026, validating its gene-editing moat.
  • The 31 January 2026 China JV with BCA preserves royalties while de-risking exposure.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Parental Leave

Employee Stock Purchase Plan

Paid Holidays

Paid Vacation

Tuition Reimbursement

Flexible Work Hours

Company News

Associated Press
Jan 23rd, 2026
Canada approves PRRSV-resistant pigs for food and feed to cut farm losses and antibiotic use

Canada has approved genetically engineered pigs resistant to porcine reproductive and respiratory syndrome viruses for use in food and feed. Health Canada and the Canadian Food Inspection Agency completed independent safety assessments following applications from Genus PLC and PIC Canada, concluding the pigs are as safe and nutritious as conventional pork. The approval addresses PRRSV, one of the most devastating virus classes affecting farmed pigs, which causes severe symptoms including breathing problems, fever and stillborn piglets. There are currently no effective treatments available. Genus PLC's PRRSV-resistant pigs are already approved in the US, Brazil, Colombia and the Dominican Republic. However, the company will not sell these pigs in Canada until receiving regulatory authorisation in other key markets. Canada's swine industry generated over $6.3 billion in farm cash receipts in 2024.

TipRanks
Oct 21st, 2024
Genus plc CFO to Retire, Successor Search Underway

Genus plc, a global leader in animal genetics, has announced the upcoming retirement of its Chief Financial Officer, Alison Henriksen, who will leave her role in July 2025 after five years with the company.

PharmiWeb
Sep 7th, 2023
Genus Plc Preliminary Results For The Year Ended 30 June 2023

SOLID PERFORMANCE AND GOOD STRATEGIC PROGRESSWEBCAST AVAILABLE AT 7:01AM GMT, 2.01 ESTLONDON--(BUSINESS WIRE)--Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2023. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its corporate, operational and financial highlights in a pre-recorded webcast at 7:01 AM GMT, 2.01 EST.Commenting on the performance and outlook, Jorgen Kokke, Chief Executive Officer, said:“The Group achieved a strong operational performance despite ongoing challenging market conditions for producers in several important markets. Revenues grew in all regions and both PIC and ABS delivered profit growth. This also enabled us to deliver record adjusted EBITDA and good cashflow for the Group. Growth in R&D investments, primarily due to the strategically important gene editing work and expansion of PIC’s elite farms, as well as higher interest costs, resulted in adjusted profit before tax consistent with the prior year.“PIC’s performance was particularly impressive, achieving a record adjusted operating profit for the year

MarketWatch
Apr 3rd, 2023
Genus Names Jorgen Kokke as Chief Executive Officer Designate

Genus PLC said Monday that it has appointed Jorgen Kokke as chief executive officer designate, effective from May 2.

PharmiWeb
Sep 8th, 2022
Genus Plc Reports Preliminary Results For The Year Ended 30 June 2022

Continued Strategic Progress in Challenging Markets. Webcast Available at 7:01AM BST, 2.01 EDT